Busulfan Injection, Solution
FDA Recall NDC 72485-210

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Busulfan (NDC 72485-210). A significant event, classified as Class II, was initiated on Dec 08, 2020 by Armas Pharmaceuticals Inc.. The reported reason for this action was: "CGMP Deviations"

This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

December 2020 Class II Recall: CGMP Deviations

Recall Number
Class II Terminated
Reason for Recall
CGMP Deviations
Initiated
Dec 08, 2020
Reported
Dec 16, 2020
Quantity
2,064 vials

Recall Profile & Regulatory Data

Event ID
86749
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Shilpa Medicare Limited
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the U.S.
Termination Date
Mar 11, 2022
Product Description
Busulfan Injection 60 mg/10 mL (6 mg/mL), For Intravenous Infusion Only, Must be diluted before use, Single Dose Vial, Sterile, Cytotoxic Agent, Rx Only, 10 mL vial, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, Vial NDC 72485-210-01, Carton NDC 72485-210-08.
Batch or Lot Expiration Information
Lot# : 7S10008B, Exp. 12/31/2020
Affected Packages Involved in this Recall
72485-210-01Product
72485-210-08Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.